Pretzel Therapeutics completed $72.5 million Series A Round funding
Sector:
Life Science
Biotech
09/12/2022
Waltham, MA USA
Pretzel Therapeutics
completed $72.5 million Series A Round funding. Investors include
Mubadala Capital (lead), ARCH Venture Partners (lead), HealthCap, Cambridge Innovation Capital, Cambridge Enterprise, Angelini Ventures, Google Ventures, Invus Capital, Eir Ventures, GU Ventures.
“We are excited to pioneer a new era in the treatment of diseases related to mitochondrial dysfunction. The expertise we have assembled and the platform technologies we have created will allow new inroads into treating both rare genetic diseases as well as common diseases of aging,” said Jay Parrish, Ph.D., Chairman of the Board and Chief Executive Officer of Pretzel. “We’re proud to be backed by an outstanding investor syndicate, with a Series A financing that will allow us to prosecute preclinical development across our pipeline and continue to build out our talented team.”
About
Pretzel Therapeutics is a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies. Pretzel was founded by leading academic experts in mitochondrial biology and is backed by a world-class investor syndicate.
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
